InMode this week announced an initial public offering of 5 million shares, for which it expects to gross $70 million.
Lake Forest, Calif.-based InMode is developing devices that use minimally invasive radio-frequency technology for plastic surgery, gynecology, dermatology, otolaryngology and ophthalmology.
InMode set the floatation at $14 per share, giving underwriters a 30-day option to purchase up to an additional 750,000 shares at the same price. Before deductions, the company expects gross proceeds to be $70 million.
Shares are slated to trade on the NASDAQ exchange under the symbol “INMD” Aug. 8 through Aug. 12, subject to the satisfaction of customary closing conditions, according to the company.